Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/64
Title: Phase II study of neoadjuvant 'supercastration' in men with high-risk prostate cancer
Epworth Authors: Corcoran, Niall
Moon, Daniel
Costello, Anthony
Bugeja, Patricia
Parente, Phillip
Hovens, Christopher
Howard, Nicholas
Kerger, Michael
Other Authors: Ruljancich, Paul
Grummet, Jeremy
Clarke, David
Pedersen, John
Ryan, Andrew
Keywords: Epworth Prostate Centre, Epworth HealthCare Richmond, Melbourne, Vic., Australia
Supercastration
High-Risk Prostate Cancer
Abiraterone
Degarelix
Bicalutamide
Prednisolone
Response Rate
Post-Prostatectomy Disease Relapse
Issue Date: Sep-2014
Citation: BJU International Volume 113, Issue Supplement S4, p 18
Abstract: Introduction: Men with high-risk prostate cancer are at increased risk of disease relapse post-prostatectomy. Previous neo-adjuvant studies demonstrate reductions in positive margin rates, but a low pT0 response rate and no improvement in biochemical recurrence-free survival. With the advent of more effective hormonal agents we wished to determine if a ‘supercastration’ combination led to an increased pT0 response rate compared to historical controls. Patients and Methods: This is an open label non-randomised Phase II study neoadjuvant study of ‘supercastration’ in men with high-risk clinically localized prostate cancer. Treatment consists of Degarelix 240/80 mg q 1/12, Abiraterone 1000 mg OD, Bicalutamide 50 mg OD and Prednisolone 5 mg OD for 24 weeks. The primary endpoints are safety/tolerability and pT0 response rate. Secondary endpoints include correlative molecular and hormonal studies. Using an optimal 2-stage design, the trial is powered to detect a pT0 response rate of 25%, with at least one pT0 response required in the first 9 patients required to trigger recruitment to the second phase. The final anticipated sample size is 12–17. Results: To date 13 patients have been recruited. The combination treatment has been well tolerated, with hot flushes and fatigue being the most commonly reported side effects. Three patients with asymptomatic elevation of liver transaminases required Abiraterone dose reductions, and there have been no unexpected toxicities. One patient in the first phase had a complete pathological response, with complete resolution of high-grade disease observed in a second patient. Conclusions: This ongoing Phase II trial will offer insights into the role of neoadjuvant ‘supercastration’ in men with high-risk prostate cancer. Correlative molecular studies will be performed to elucidate molecular mechanisms of resistance in persistent tumour tissue.
DOI: doi/10.1111/bju.12618
URL: http://onlinelibrary.wiley.com/doi/10.1111/bju.12618/epdf
ISSN: 1464-410X
1464-4096
Journal Title: BJU International
Type: Journal Article
Affiliated Organisations: University of Melbourne
Alfred Hospital
Monash University
Eastern Health
Royal Melbourne Hospital
Type of Clinical Study or Trial: Clinical Trial
Appears in Collections:Cancer Services
Epworth Prostate Centre

Files in This Item:
There are no files associated with this item.


Items in EKB are protected by copyright, with all rights reserved, unless otherwise indicated.